CARDIOPHARMA ApS: Financial statements 2022
CVR: 13966273
Source: annual report 2022, Danish Business Authority
01/05/2021 – 30/04/2022
CARDIOPHARMA ApS (CVR 13966273) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 3,438,346 and a net result of DKK 2,900,689 compared with DKK 4,278,587 the year before. That is an increase of 323.9% compared with the year before. Equity in the 2022 report amounted to DKK 27,981,353. The solvency ratio was 99.7%. The company had 1 employee in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK 3,438,346
- Profit/Loss
- DKK 2,900,689
- Equity
- DKK 27,981,353
- Total Assets
- DKK 28,073,353
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | 3.4M | 2.9M | 28M | 1 |
| 2021 | 0 | 811K | 4.3M | 30.1M | 1 |
| 2020 | - | 2.4M | 1.6M | 26.2M | 1 |
| 2019 | - | 1.8M | 1.7M | 25M | 1 |
| 2018 | - | 35K | 1.1M | 24.3M | - |
Official annual report
Keep an eye on CARDIOPHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout CARDIOPHARMA ApS
CARDIOPHARMA ApS is a Danish company of the type Anpartsselskab based in Gentofte, founded in 1990. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named KM 455 ApS. The management consists of Niels Christian Fischer Petersen. The company is owned by Niels Christian Fischer Petersen. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported a gross profit of DKK 4,336,132 and a net result of DKK 3,090,043 compared with DKK 1,968,388 the year before. Equity in the 2026 report amounted to DKK 31,593,726.